Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis

Table 3 Biochemical parameters of the study population (baseline)

Variables (mean ± SD)	Healthy subjects (n = 40)	cACLD patients (n = 150)	P value1
AST (IU/L)	31.30 ± 10.14	48.74 ± 54.09	< 0.0001
ALT (IU/L)	39.37 ± 17.57	70.02 ± 15.05	< 0.0001
Bilirubin (µmol/L)	15.98 ± 1.74	25.86 ± 7.53	< 0.0001
PLT count (mm3)	242.6 ± 42.76	155.7 ± 61.56	< 0.0001
RDW-CV (%)	14.40 ± 2.28	21.04 ± 15.20	< 0.0001
RDW-SD (fL)	40.19 ± 4.48	56.27 ± 10.54	< 0.0001
Albumin (g/L)	44.2 ± 0.29	26.35 ± 8.48	< 0.0001
INR	1.02 ± 0.38	1.78 ± 1.11	NS
HOMA-IR	1.77 ± 0.54	3.15 ± 1.52	< 0.0001
Insulin (µu/mL)	7.03 ± 1.52	11.67 ± 3.259	< 0.0001
FPG (mg/dL)	100.7 ± 9.35	120.9 ± 17.48	< 0.0001
Total cholesterol (mg/dL)	135.2 ± 42.07	185.2 ± 44.12	< 0.0001
HDL (mg/dL)	95.93 ± 27.29	42.37 ± 9.92	< 0.0001
LDL (mg/dL)	44.73 ± 9.67	126.1 ± 39.78	< 0.0001
Tryglicerides (mg/dL)	109.5 ± 32.14	150.6 ± 63.39	0.002
Creatinine (mg/dL)	0.97 ± 0.23	1.48 ± 3.88	0.03

¹Mann-Whitney U test.

Statistically significant differences (P < 0.05) are reported in bold. AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; PLT: Platelets count; CV: Coefficient Variation; RDW: Red-cell distribution width; INR: International normalized ratio; HOMA-IR: homeostasis model assessment for insulin resistance; NS: Not statistically significant; cACLD: Compensated advanced chronic liver disease.